Molecular biology · Bioinfo & AI
Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer
Summary
This study aimed to develop a mutational signature-based biomarker (MSBM) to define homologous recombination deficiency (HRD) in advanced ovarian cancer, overcoming limitations of genomic scar-based assays. The MSBM integrates tumor-BRCA mutation status, Mutational Signature 3 similarity score, and the absence of CCNE1 amplification, derived from whole-exome sequencing. A phase II trial (MSBM-OL) validated this biomarker and evaluated the efficacy of olaparib maintenance monotherapy in HRD-positive patients. The study demonstrated that olaparib significantly extended progression-free survival (22.3 months) compared to a predefined 9-month threshold, confirming its clinical benefit as first-line maintenance therapy.
Critical appraisal
Clinical. This phase II trial (MSBM-OL) demonstrates a significant clinical benefit of olaparib as first-line maintenance monotherapy for patients with advanced high-grade ovarian cancer who are HRD-positive by MSBM and have responded to platinum-doublet chemotherapy. The median progression-free survival of 22.3 months in the olaparib arm significantly exceeded the predefined 9-month threshold (p < 0.001), suggesting a major clinical impact. The MSBM biomarker is predictive of response to olaparib. Grade ≥ 3 adverse events were manageable (anemia 25.5%, neutropenia 12.8%). These results could justify phase III trials and potentially change clinical practice for selecting patients eligible for olaparib within 1-3 years.
Molecular biology. The development of MSBM represents a significant advance in HRD assessment, overcoming the limitations of genomic scar-based assays. This novel biomarker integrates three whole-exome sequencing (WES)-derived features: tumor-BRCA mutation status, a Mutational Signature 3 similarity score, and the absence of CCNE1 amplification. Using WES for HRD evaluation offers a robust and comprehensive method. The 81% concordance with the myChoice CDx test and correlation with genomic instability scores (R = 0.63) validate the analytical approach of MSBM. If validated on a larger scale, this test could be integrated into molecular diagnostic platforms to guide therapeutic decisions.
Bioinfo & AI. The MSBM is an innovative algorithm that integrates whole-exome sequencing-derived features to assess HRD without relying on genomic scars. Its architecture combines tumor-BRCA mutation status, Mutational Signature 3, and CCNE1 amplification status. The study showed that MSBM enables robust HRD evaluation, with 99.5% patient evaluability. While explicit details on algorithmic implementation (open-source code, pre-trained models) are not mentioned, MSBM’s ability to identify a large subset of HRD-positive patients (72.4%) suggests potential for improved patient selection. Its clinical deployment could streamline workflows by providing comprehensive HRD assessment from WES data, thereby facilitating targeted treatment decisions.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology